Cantor Fitzgerald Increases Amgen (NASDAQ:AMGN) Price Target to $350.00

Amgen (NASDAQ:AMGN) had its target price raised by analysts at Cantor Fitzgerald from $315.00 to $350.00 in a research note issued to investors on Wednesday, MarketBeat reports. The firm currently has a “neutral” rating on the medical research company’s stock. Cantor Fitzgerald’s target price indicates a potential downside of 4.84% from the stock’s current price.

Several other research firms have also recently weighed in on AMGN. BMO Capital Markets increased their price objective on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Oppenheimer set a $400.00 price target on shares of Amgen and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a research note on Tuesday, January 20th. Piper Sandler increased their target price on shares of Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Finally, Erste Group Bank raised shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $347.65.

Amgen Stock Up 0.4%

Amgen stock opened at $367.80 on Wednesday. The company’s 50-day moving average price is $333.66 and its two-hundred day moving average price is $310.84. The company has a quick ratio of 0.99, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock has a market cap of $198.05 billion, a P/E ratio of 25.85, a P/E/G ratio of 3.20 and a beta of 0.46. Amgen has a twelve month low of $261.43 and a twelve month high of $374.90.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts expect that Amgen will post 20.62 EPS for the current year.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 890 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the sale, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 10,908 shares of company stock valued at $3,674,966. Company insiders own 0.76% of the company’s stock.

Hedge Funds Weigh In On Amgen

A number of institutional investors have recently modified their holdings of AMGN. Laurel Wealth Advisors LLC raised its stake in Amgen by 27,765.8% during the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after acquiring an additional 6,676,575 shares in the last quarter. Norges Bank bought a new stake in shares of Amgen during the 2nd quarter valued at approximately $1,663,726,000. Capital World Investors increased its position in Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares in the last quarter. Vanguard Group Inc. increased its position in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares in the last quarter. Finally, National Bank of Canada FI lifted its stake in Amgen by 237.7% in the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after purchasing an additional 863,216 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat Street estimates and management issued a robust 2026 outlook, driven by double‑digit revenue and EPS growth and strong new‑product uptake — a primary driver of the rally. Amgen Q4 results beat Street estimates
• Positive Sentiment: Several brokerages raised price targets (notably Goldman Sachs to $415 and RBC/Leerink upgrades), lending credibility to upside expectations and supporting institutional buying interest. Goldman Sachs adjusts price target on Amgen
• Positive Sentiment: Momentum indicators and flow show Amgen near 52‑week highs with reports of institutional accumulation, reinforcing sentiment that the company’s growth trajectory is being re‑rated. Amgen Stock Hits 52-Week Highs: Buy Signal?
• Neutral Sentiment: Amgen reported completion of postmarketing work on IMLYGIC’s melanoma safety study and updates on the FORTITUDE‑301 trial; these procedural milestones reduce uncertainty but are unlikely to move the needle until detailed data or regulatory actions follow. IMLYGIC safety study reaches completion
• Neutral Sentiment: Analyst coverage is mixed: some firms reiterate holds or lower relative targets even as others are bullish, creating a split narrative on valuation vs. execution risk. Analyst: new-product uptake offset by legacy erosion
• Negative Sentiment: CVS Health will remove Amgen and Lilly bone‑disease treatments from some preferred drug lists effective April 1, substituting lower‑cost alternatives — a clear near‑term sales headwind for affected products and a reason for investor caution. CVS to drop Amgen and Lilly bone disease treatments

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.